Clinical trials: Rosacea
Facial Papulopustular Rosacea
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
- Trial name
- NCT04608500
- Testing
- FMX103 minocycline foam 1.5%, Vehicle foam
- Where
- 46 sites in United States
- Volunteers
- 771 people
- Sponsor
- Vyne Therapeutics Inc.
Papulopustular Rosacea
Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea
This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer…
- Trial name
- NCT03079531
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Anne Chang
Papulopustular Rosacea
Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea
This study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment of papulopustular rosacea. The study will test the active ingredient plus foam against foam alone.
- Trial name
- NCT01025635
- Testing
- Azelaic acid foam 15%, Vehicle foam
- Where
- 20 sites in United States
- Volunteers
- 401 people
- Sponsor
- LEO Pharma
Rosacea
A Study to Assess the Efficacy, Safety and Tolerability of DFD-04
The purpose of this exploratory study is to assess the efficacy, safety and tolerability of DFD-04 Ointment for topical treatment of rosacea over 12 weeks of treatment.
- Trial name
- NCT02828241
- Testing
- DFD-04 Ointment
- Where
- 8 sites in Germany
- Volunteers
- 61 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Papulopustular Rosacea
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.
- Trial name
- NCT03276936
- Testing
- FMX103 1.5%
- Where
- 79 sites in United States
- Volunteers
- 504 people
- Sponsor
- Vyne Therapeutics Inc.
Papulopustular Rosacea
An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
This study is designed to investigate whether topical application of a cromolyn sodium solution is able to decrease the facial redness seen in patients with papulopustular rosacea. Previous work in the lab of Dr.
- Trial name
- NCT01933464
- Testing
- Cromolyn Sodium, Normal Saline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego
Corneal Neovascularization
Treatment of Corneal Neovascularization With Topical Pazopanib
The purpose of this study is to determine the safety and efficacy of a drug [Pazopanib (Votrient)] as a treatment for corneal neovascularization.
- Trial name
- NCT01257750
- Testing
- Pazopanib (5mg/ml)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Reza Dana, MD